Crestor RAPID (The efficacy of RosuvAstatin for korean dyslipidemia PatIents with Diabetes) - RAPID

Study identifier:NIS-CKR-CRE-2007/3

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

RAPID (Evaluating the efficacy of RosuvAstatin for korean dyslipidemia PatIents with Diabetes in real world practice)

Medical condition

Dyslipidemia

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

5000

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Jun 2007

Primary Completion Date: 01 Aug 2007

Study Completion Date: 01 Dec 2007

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2010 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Seoul, Songpa-gu, Republic of Korea

Location

Research Site

Seoul, Jongro-gu, Republic of Korea

Location

Research Site

Seoul, Kangnam-gu, Republic of Korea

Arms	Assigned Interventions

Documents available

http://www.astrazeneca.com/node/emailtriage.aspx
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Korea Clinical Study

82-2-2188-2146

hyejin.kang@astrazeneca.com

Investigators

Principal Investigator

Hyunah Caroline Choi

AstraZeneca Korea

Crestor RAPID (The efficacy of RosuvAstatin for korean dyslipidemia PatIents with Diabetes) - RAPID

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Documents available

http://www.astrazeneca.com/node/emailtriage.aspx

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator